Efficacy of fluvoxamine in treatment-refractory depression

Pedro L. Delgado, Lawrence H. Price, Dennis S. Charney, George R. Heninger

Research output: Contribution to journalArticle

74 Scopus citations

Abstract

The efficacy of the potent and selective unicyclic serotonin reuptake inhibitor, fluvoxamine, was evaluated in 38 consecutively admitted depressed patients judged refractory to standard antidepressants using operationalized criteria. Twenty-eight patients completed a single-blind protocol involving ≥2 weeks of placebo and 4-6 weeks of active fluvoxamine. Eight (29%) were judged responders to fluvoxamine alone, eight (29%) responded to lithium augmentation of fluvoxamine and two (7%) responded to fluvoxamine, lithium and perphenazine. These data suggest that selective and potent serotonin reuptake inhibitors may be effective in patients refractory to generally available antidepressant medications.

Original languageEnglish (US)
Pages (from-to)55-60
Number of pages6
JournalJournal of Affective Disorders
Volume15
Issue number1
DOIs
StatePublished - Jan 1 1988

Keywords

  • Fluvoxamine
  • Lithium
  • Treatment-refractory depression

ASJC Scopus subject areas

  • Clinical Psychology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Efficacy of fluvoxamine in treatment-refractory depression'. Together they form a unique fingerprint.

  • Cite this

    Delgado, P. L., Price, L. H., Charney, D. S., & Heninger, G. R. (1988). Efficacy of fluvoxamine in treatment-refractory depression. Journal of Affective Disorders, 15(1), 55-60. https://doi.org/10.1016/0165-0327(88)90009-2